In the dynamic field of cardiovascular medicine, precise and effective anticoagulation is paramount. Bivalirudin, a synthetic peptide with the CAS number 128270-60-0, has emerged as a cornerstone in modern therapeutic strategies. As a specific, reversible, and direct thrombin inhibitor (DTI), Bivalirudin plays a critical role in preventing thrombotic events, particularly during invasive cardiac procedures.

Understanding Bivalirudin's Mechanism and Advantages

Bivalirudin's efficacy stems from its ability to directly bind to both the catalytic site and the anion-binding exosite of thrombin. This dual action ensures potent inhibition of thrombin, a key enzyme in the coagulation cascade. Unlike traditional anticoagulants like heparin, Bivalirudin offers several distinct advantages. It has a short plasma half-life, approximately 25 minutes in patients with normal renal function, leading to a predictable anticoagulant response. Crucially, Bivalirudin does not bind to plasma proteins or red blood cells, minimizing the risk of heparin-induced thrombocytopenia (HIT) and heparin-induced thrombosis-thrombocytopenia syndrome (HITT). This makes it a safer alternative for patients at risk of these serious complications.

Applications in Percutaneous Coronary Intervention (PCI)

One of the primary applications for Bivalirudin is in percutaneous coronary intervention (PCI). Whether patients have unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), or ST-segment elevation myocardial infarction (STEMI), Bivalirudin serves as an essential procedural anticoagulant. Clinical studies, such as REPLACE-2 and HORIZONS-AMI, have demonstrated that Bivalirudin monotherapy provides comparable or superior outcomes to heparin combined with glycoprotein IIb/IIIa inhibitors, often with a significantly lower incidence of major bleeding events. This improved safety profile makes Bivalirudin a preferred choice for many cardiologists. If you are looking to buy Bivalirudin CAS 128270-60-0 for these critical procedures, sourcing from a reputable manufacturer in China is key.

Quality and Sourcing: The Importance of a Reliable Supplier

For pharmaceutical applications, the purity and consistency of active pharmaceutical ingredients (APIs) and intermediates are non-negotiable. Bivalirudin is typically supplied with a high purity assay, often 99.5% or higher. As a dedicated Bivalirudin supplier, it is vital to partner with a manufacturer that guarantees these stringent quality standards. Sourcing pharmaceutical intermediates requires trust in the supply chain, ensuring that the product meets all regulatory and performance requirements. When you purchase Bivalirudin, consider the expertise and quality control measures of the supplier to ensure the integrity of your final product. A reliable China manufacturer can offer competitive pricing while maintaining the high standards required for pharmaceutical intermediates.

Conclusion

Bivalirudin (CAS 128270-60-0) stands as a critical anticoagulant in modern medicine, offering significant therapeutic advantages, particularly in cardiovascular interventions. Its specific, reversible thrombin inhibition and favorable safety profile make it an indispensable pharmaceutical intermediate. For healthcare providers and researchers seeking high-quality Bivalirudin, partnering with an established Bivalirudin supplier in China ensures access to a reliable and cost-effective solution. We are committed to providing top-tier Bivalirudin to support your medical advancements and meet your procurement needs.